GondolaBio

GondolaBio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines for individuals living with genetic diseases. With a strong commitment to addressing high unmet needs, GondolaBio leverages cutting-edge biological research to create breakthrough therapies across a range of therapeutic areas and modalities. Operating from its primary address at 3160 Porter Dr, Palo Alto, California 94304, US, GondolaBio is driven by a team of experienced drug discoverers, developers, and innovators focused on translating advances in genetic science into impactful medicines.

GondolaBio aims to accelerate the availability of new treatments, focusing on speed and efficiency in bringing novel therapeutics to patients. The company’s approach encompasses all stages of drug development, from early discovery to clinical trials, ensuring a comprehensive and integrated strategy. GondolaBio’s commitment extends beyond the laboratory, with a focus on improving the lives of patients and families affected by genetic conditions. The biotechnology research conducted at GondolaBio is designed to make a tangible difference in healthcare outcomes.

GondolaBio’s mission is to develop meaningful medicines that offer hope and improved quality of life for patients. As a sister company of BridgeBio Pharma, GondolaBio benefits from a network of resources and expertise that supports its ambitious goals. We invite the management team at GondolaBio to enhance your company's visibility by creating a customized and exclusive company showcase and product listing on our platform, providing a direct connection to potential partners and customers.